Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MeDSuN Surveillance Network To Select Facilities Via Probability Sampling

This article was originally published in The Gray Sheet

Executive Summary

A multi-stage sampling process could prove less costly than a random sampling approach for selecting user facilities for the national Medical Device Surveillance Network (MeDSuN), FDA's Center for Devices and Radiological Health contends.

You may also be interested in...



MeDSuN Pilot Funding Included In Budget; Program To Begin In Six Months

Funded at $1.7 mil. in FDA's FY 2001 budget, the Medical Device Surveillance Network (MeDSuN) reporting system pilot is expected to become operational within six months, according to Center for Devices and Radiological Health Office of Surveillance and Biometrics Deputy Director Susan Gardner.

MeDSuN Pilot Funding Included In Budget; Program To Begin In Six Months

Funded at $1.7 mil. in FDA's FY 2001 budget, the Medical Device Surveillance Network (MeDSuN) reporting system pilot is expected to become operational within six months, according to Center for Devices and Radiological Health Office of Surveillance and Biometrics Deputy Director Susan Gardner.

FDA Sentinel Program Increases Adverse Event Reporting By User Facilities

The average level of medical device adverse event reporting increased significantly under FDA's one-year Sentinel feasibility study concluded last year, according to a report submitted June 16 by Coda, the contractor organization facilitating the pilot.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012488

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel